10 Best Healthcare Stocks for a Long-Term Portfolio

Healthcare is a foundational industry for long-term investing. As populations grow and age, medical needs increase, and new treatments revolutionize patient care, the sector’s importance only grows greater. Building a portfolio that includes top healthcare stocks can add both stability and long-term growth, making it ideal for both beginners and seasoned investors.

Table of Contents

Why Invest in Healthcare for the Long Term?

Defensive Nature: Healthcare is a necessity—spending remains consistent regardless of the economy.
Innovation-Driven Growth: Biotechnology, diagnostics, and pharmaceuticals push the sector continually forward.
Favorable Demographics: An aging global population ensures sustained healthcare demand for decades.
Regulatory Resilience: Many healthcare businesses have adapted to regulatory environments, ensuring revenue stability.
Portfolio Diversification: The sector offers stability, even when other market sectors are volatile.

Check out 9 Reasons to Stay Away from Penny Stocks

10 Healthcare Stocks for a Long-Term Portfolio

The following represents a carefully selected list of ten industry-leading companies spanning pharmaceuticals, hospitals, and life sciences. Each is suited for a long-term approach, thanks to its financial strength, innovative prowess, and sector leadership.

Stock Name	Sector/Industry	Key Strengths	Why Long-Term?
Sun Pharmaceutical Industries Ltd	Pharmaceuticals	Largest pharma in India, global reach, robust R&D	Leadership, diversified pipeline, global trust
Dr. Reddy’s Laboratories Ltd	Pharmaceuticals	Strong generics, biosimilars, global expansion	Resilient growth, innovation
Cipla Ltd	Pharmaceuticals	Chronic care leader, global presence, strong balance sheet	Chronic demand, regulatory reliability
Divi’s Laboratories Ltd	API & Life Sciences	Export leader, efficiency, R&D focus	Reliable supplier, high margins
Lupin Ltd	Pharmaceuticals	U.S. generics growth, emerging market expansion	Improving profit, debt-free
Apollo Hospitals Enterprise Ltd	Hospitals & Diagnostics	Largest private hospital chain, tech innovation	Leadership in healthcare delivery
Max Healthcare Institute Ltd	Hospitals & Services	Urban focus, operational excellence	Rising urban healthcare demand
Aurobindo Pharma Ltd	Pharmaceuticals	Export-led, strong pipeline, regulatory-approved	Revenue/earnings consistency
Fortis Healthcare Ltd	Hospitals	Premium care, diagnostics growth	Medical tourism, urban expansion
Zydus Lifesciences Ltd	Pharmaceuticals	Vaccine leader, global expansion, biosimilars	Focus on R&D, innovation

Best Healthcare Stocks for a Long-Term Portfolio

Read 9 Powerful Tips for Investing in ETFs for Long-Term Wealth

Why Each Stock Deserves a Place in Your Long Term Portfolio

Here are the recent financial performance, operational strengths, growth metrics, and other compelling reasons to consider these names for a long-term portfolio.

1. Sun Pharmaceutical Industries Ltd

Snapshot: India’s largest pharmaceutical company, Sun Pharma, is globally recognized with operations in over 100 countries.
Financial Stats (Q1 FY26):
- Total income: ₹14,315.9 crore (up 8.6% YoY)
- Operating profit: ₹4,302 crore
- Profit after tax: ₹2,293 crore
- EPS: ₹9.50
- Inventory turnover: 5.08x
- Dividend per share: ₹16.00
Why Long-Term?
- Consistently growing revenues and profits.
- Robust global supply network and strong domestic footprint.
- High focus on R&D and innovative drug launches.
- Leader in specialty drugs and generics.

2. Dr. Reddy’s Laboratories Ltd

Snapshot: Excels in affordable generics and biosimilars, active in over 50 countries.
Financial Stats (Q1 FY26):
- Revenue: ₹8,545 crore (up 11% YoY)
- Gross margin: 56.9%
- R&D spend: 7.3% of revenue
- Net profit: ₹1,418 crore (up 2% YoY)
- India business: grew 11% YoY this quarter
Why Long-Term?
- Expanding global footprint with strong growth in Europe and emerging markets.
- Ongoing product launches and robust pipeline.
- Strong balance sheet and continuous investment in innovation.

3. Cipla Ltd

Snapshot: Focuses on chronic therapies, respiratory, anti-retroviral, and cancer drugs.
Financial Stats (FY25):
- Total revenue: ₹27,548 crore (up 8% YoY)
- EBITDA margin: 25.9%
- Net profit: ₹5,273 crore (up 28% YoY)
- R&D investment: ₹426 crore/quarter (6.3% of sales)
Why Long-Term?
- Market leader in respiratory and chronic therapies.
- Strong growth across India, North America, Africa, and Europe.
- High cash reserves and sound regulatory track record.

4. Divi’s Laboratories Ltd

Snapshot: Among the world’s leading manufacturers of APIs and nutraceutical ingredients.
Financial Stats (Q4 FY25):
- Net sales: ₹2,585 crore (5-quarter high)
- Operating profit: ₹885 crore (margin 34.2%)
- Net profit: ₹662 crore; EPS: ₹24.98
Why Long-Term?
- Focused on high-growth API export business.
- Exceptionally strong operational efficiency and margins.
- Supplier to global pharma leaders.

5. Lupin Ltd

Snapshot: Global presence with a focus on U.S. generics, India, and emerging pharma markets.
Financial Stats (FY25):
- Total sales: ₹22,192 crore (up 12.9% YoY)
- Profit after tax: ₹3,306 crore (up 70.8% YoY)
- EBITDA margin: 24.7%
- Dividend payout: 600% recommended
Why Long-Term?
- Significant growth in U.S., India, and emerging markets.
- Improving profit margins due to operational efficiencies.
- Debt-free status, innovation-led growth.

6. Apollo Hospitals Enterprise Ltd

Snapshot: India’s largest private hospital network, known for complexity and innovation in care.
Financial Stats (FY25):
- Market cap: ₹1,05,703 crore
- Landmark: Over 25,000 transplants performed
Why Long-Term?
- Leader in high-value tertiary and quaternary care.
- First-mover in telemedicine and digital healthcare delivery.
- Rising insurance penetration and premium patient segment.

7. Max Healthcare Institute Ltd

Snapshot: Urban-focused, high-quality hospital and diagnostic care provider.
Financial Stats:
- FY24 revenue: ₹5,437 crore (up 19% YoY)
- Network TOI (FY24): ₹6,849 crore
- EBITDA: ₹1,840 crore
- Average revenue per occupied bed grew 12% to ₹75,800
Why Long-Term?
- Extending market dominance via strategic acquisitions.
- Strong international medical tourism and rising OPD footfall.
- Urbanization drives demand for its specialized services.

8. Aurobindo Pharma Ltd

Snapshot: Significant export business, robust pipeline in generics and specialty drugs.
Financial Stats (Q4 FY25):
- Total income: ₹7,716 crore (up 16.8% YoY)
- PAT: ₹907 crore (up 79.4% YoY)
- EPS: ₹15.50 (up 80.2% YoY)
Why Long-Term?
- Consistent revenue and earnings growth year-over-year.
- Global regulatory approvals and cost leadership.
- Strong investment in product innovation.

9. Fortis Healthcare Ltd

Snapshot: Leading pan-India hospital chain, focused on premium acute care and diagnostics.
Financial Stats:
- Market cap: ₹64,870 crore
- Noted 72% YoY return in recent cycles (mid 2025)
Why Long-Term?
- Increased healthcare expenditure by India’s middle class.
- Key beneficiary of rising medical tourism.
- Expansion into high-margin diagnostics and wellness.

10. Zydus Lifesciences Ltd

Snapshot: Leading in biosimilars, vaccines, and wellness products.
Financial Stats:
- Market cap: ~₹95,500 crore
- Strong YoY earnings and pipeline growth
Why Long-Term?
- Pioneer in affordable vaccines and biosimilars.
- Aggressive global expansion—presence in 50+ countries.
- Consistent focus on R&D and IP creation.

Check out Is It the Right Time to Buy Bajaj Auto Ltd Stock?

Key Financial Metrics

Company	FY25/FY26 Revenue (₹ Cr)	Net Profit (₹ Cr)	EBITDA Margin (%)	Dividend (₹/share)	Market Cap (₹ Cr)
Sun Pharma	14,315 (latest Qtr.)	2,293 (latest Qtr.)	~31	16.00 (FY25)	3,91,019
Dr. Reddy’s	8,545 (latest Qtr.)	1,418 (latest Qtr.)	26.7	40 (est. FY25)	1,01,599
Cipla	27,548 (FY25)	5,273 (FY25)	25.9	12 (FY25)	1,21,395
Divi’s Labs	2,585 (latest Qtr.)	662 (latest Qtr.)	34.2	30 (est. FY25)	1,68,878
Lupin	22,192 (FY25)	3,306 (FY25)	24.7	60 (FY25)	85,288
Apollo Hospitals	1,05,703 (Mkt Cap)	–	13 (est. FY24)	12 (est. FY25)	1,05,703
Max Healthcare	5,437 (FY24)	1,170 (est. FY24)	27+	2.4 (est. FY24)	1,21,129
Aurobindo	7,716 (latest Qtr.)	907 (latest Qtr.)	~20 (est. FY25)	2.8 (FY25)	62,715
Fortis	64,870 (Mkt Cap)	460 (FY24 est)	15 (FY24 est)	1.2 (FY25)	64,870
Zydus	9,540 (latest Qtr. est.)	1,182 (latest Qtr.)	22 (FY25 est)	12.0 (FY25 est.)	95,500

Key Factors for Long-Term Stock Selection

Financial Health: Focus on stable revenue growth, big margins, and strong profits.
Business Strength: Look for diversified portfolios and global market reach.
Innovation Track Record: Choose companies with big investments in R&D and cutting-edge product launches.
Solid Management: Experienced leadership is critical for stability and innovation.
Sector Resilience: All selected stocks have demonstrated the ability to weather market and regulatory changes.

Check out Top 5 Undervalued Stocks to Buy in 2025 for Long-Term Wealth Creation

What Risks Should Beginners Look Out For?

Regulatory Decisions: Changing government policies or price controls can affect profits.
Patent Expirations: Loss of exclusivity on drugs can lower revenue for pharma firms.
Competition: Fast-moving innovation means new entrants and tech disruptions are always a risk.
Compliance Issues: Quality warnings or recalls can hurt brand value and share prices.
Geopolitical and Export Risks: Firms selling globally can be exposed to trade or political turmoil.

Bonus Tips for Healthcare Investing Beginners

Diversify, Always: Spread investments across different companies and market segments.
Reinvest Dividends: Compounding your returns can dramatically boost your long-term gains.
Use Systematic Investing (SIPs): Investing regularly can reduce volatility.
Stay Updated: Monitor company reports and relevant healthcare news.
Patience Wins: Don’t react to short-term price swings; healthcare rewards patient investors.

Conclusion

A portfolio built around these ten healthcare stalwarts provides a superb mix of scale, innovation, financial strength, and sector leadership. Whether you’re just starting or looking to rebalance for long-term success, these companies offer a solid foundation for harnessing the growth and stability of India’s dynamic and evolving healthcare sector.